Dossier assessment

Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A22-132
Last updated

Report documents

  1. Extract of dossier assessment

    Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 743 kB, EN, not accessible
  2. Dossier assessment

    Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible

Dossier assessment

Indication:

Patients with relapsed/refractory chronic lymphocytic leukaemia

Result of dossier assessment:
  • who have not yet received a Bruton tyrosine kinase (BTK) inhibitor and/or B-cell lymphoma-2 (BCL-2) inhibitor
    < 65 years: hint of major added benefit
    ≥ 65 years: hint of minor added benefit
  • after prior therapy with at least one BTK inhibitor: added benefit not proven
  • after prior therapy with at least one BCL-2 inhibitor: added benefit not proven
  • after prior therapy with at least one BTK inhibitor and one BCL-2 inhibitor: added benefit not proven

Press releases

Zanubrutinib in chronic lymphocytic leukaemia: added benefit for certain patients

For adults with relapsed/refractory CLL who have not yet received a BTK or BCL-2 inhibitor, the drug has major or minor added benefit compared with ibrutinib, depending on the patients’ age.

Project details

Project no.
A22-132
Commission
Commission awarded on 12.12.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Zanubrutinib (marginal zone lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-131
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Zanubrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-130
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Zanubrutinib (Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-169
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-130
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form